US will restore $1B for California's troubled bullet train

Friday, June 11, 2021 | The Associated Press


In this Feb. 26, 2015, file photo, a full-scale mock-up of a high-speed train is displayed at the Capitol in Sacramento, Calif. The federal government has reached an agreement to restore nearly $1 billion in funding for California's troubled bullet train. Gov. Gavin Newsom announced night, Thursday, June 10, 2021, that the U.S. Department of Transportation finalized settlement negotiations to restore money for the high-speed rail project that the Trump administration revoked in 2019. (AP Photo/Rich Pedroncelli, File)

SACRAMENTO, Calif. (AP) — The federal government has reached an agreement to restore nearly $1 billion in funding for California's troubled bullet train, Gov. Gavin Newsom announced.

The U.S. Department of Transportation finalized settlement negotiations to restore the money for the high-speed rail project that was revoked by the Trump administration in 2019, Newsom said Thursday night.

The restoration of $929 million in grant funding “will continue to spur job creation, advance the project and move the state one step closer to getting trains running in California as soon as possible," Newsom said in a statement.

California voters in 2008 approved nearly $10 billion in bond money to build a high-speed rail line connecting Los Angeles and San Francisco that was supposed to be running by 2020.

But the project was plagued by cost overruns and delays. Officials now hope to have trains running on a segment through the state's central valley agricultural region by 2029.

Critics have derided the segment as a “train to nowhere,” but supporters say it’s a necessary test and precursor to linking more populated areas.

The project's business plan anticipates environmental approval for the 500 miles (805 kilometers) between Los Angeles and San Francisco by 2023. Completion of the full line depends on funding and other unknowns.

Newsom last month unveiled a budget proposal that includes $4.2 billion for the project, including the bond money approved by voters in 2008.

Featured Article: What are popular range trading strategies?


7 Healthcare Stocks Delivering Innovation in 2021

We all knew that traditional healthcare services were disrupted in 2020. The patient-doctor relationship went virtual. In the early months of the pandemic, many people in need of elective surgeries simply did not have that option available to them. And even local pharmacies took on a new e-commerce role as curbside pickup or home delivery of prescription medication became the norm.

Not surprisingly healthcare stocks were battered last year. Overall, the sector was down 11%, far below the S&P 500 Index that climbed over 15%.

However, the market is always forward-looking with a particular eye towards innovation. The healthcare sector has many companies that are developing innovative approaches in areas such as gene editing. And other companies are in late-stage trials for drugs that can deliver breakthrough results for conditions that continue to plague our world.

That’s the focus of this presentation. We’ve identified 7 healthcare stocks that are delivering innovative ideas that will help deliver better patient outcomes. And in some cases will revolutionize medicine altogether. These are also the stocks that analysts have their eye on.

View the "7 Healthcare Stocks Delivering Innovation in 2021".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.